Table 1.
Baseline Demographic and Clinical Characteristics of Study Population
| All Patients (n=931) | UC Group (n=466) | PC Group (n=465) | ||
|---|---|---|---|---|
| Age, years | Mean ± SD | 42.35±1.9 | 42.85±1.7 | 41.84±1.7 |
| <40 | 439 (47.15%) | 213 (45.7%) | 226 (48.6%) | |
| 41–60 | 439 (47.15%) | 225 (48.3%) | 214 (46.0%) | |
| >60 | 53 (5.7%) | 28 (6.0%) | 25 (5.4%) | |
| Sex | Males | 418 (44.9%) | 215 (46.1%) | 203 (43.7%) |
| Females | 513 (55.1%) | 251 (53.9%) | 262 (56.3%) | |
| Residence | Urban | 671 (72.1%) | 329 (70.6%) | 342 (73.6%) |
| Rural | 260 (27.9%) | 137 (29.4%) | 123 (26.4%) | |
| Liver-health status | Cirrhotic | 109 (11.7%) | 47 (10.1%) | 62 (13.3%) |
| Noncirrhotic | 822 (88.3%) | 419 (89.9%) | 403 (86.7%) | |
| Diagnosis | HCV/CHC | 905 (97.2%) | 458 (98.3%) | 447 (96.1%) |
| HCV + comorbidities | 26 (2.8%) | 8 (1.7%) | 18 (3.8%) | |
| Genotype | Untypeable/mixed | 8 (0.8%) | 2 (0.4%) | 6 (1.3%) |
| 1/1a | 9 (1.0%) | 4 (0.9%) | 5 (1.1%) | |
| 1b | 4 (0.4%) | 3 (0.6%) | 1 (0.2%) | |
| 3a | 899 (96.6%) | 451 (96.8%) | 448 (96.3%) | |
| 3b | 11 (1.2%) | 6 (1.3%) | 5 (1.1%) | |
| Treatment history | Naïve | 920 (98.8%) | 459 (98.5%) | 461 (99.1%) |
| Previously treated | 11 (1.2%) | 7 (1.5%) | 4 (0.9%) | |
| Viral load (baseline) |
Very low viremia | 24 (2.6%) | 13 (2.8%) | 11 (2.4%) |
| Low viremia | 22 (2.4%) | 13 (2.8%) | 9 (1.9%) | |
| Moderate | 287 (30.8%) | 139 (29.8%) | 148 (31.8%) | |
| High viremia | 275 (29.5%) | 139 (29.8%) | 136 (29.2%) | |
| Positive | 323 (34.7%) | 162 (34.8%) | 161 (34.6%) | |
| Treatment choices | Sof/Rv | 608 (65.3%) | 307 (65.9) | 301 (64.7) |
| Sof/Dac/Rv | 201 (21.5%) | 98 (21.0) | 103 (22.2) | |
| Sof/Dac | 122 (13.1%) | 61 (13.1) | 61 (13.1) | |
Abbreviations: HCV, hepatitis C virus; CHC, chronic hepatitis C; Sof, sofosbuvir; Rv, ribavirin; Dac, daclatasvir; UC, usual care; PC, pharmaceutical care.